Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Amendment No. 3 modifies Amneal Pharmaceuticals LLC’s term-loan credit agreement with JPMorgan Chase Bank as administrative agent.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Amendment No. 3 modifies Amneal Pharmaceuticals LLC’s term-loan credit agreement with JPMorgan Chase Bank as administrative agent
- Repricing amendment targets borrowing-cost savings, potentially improving cash flow and debt-service capacity
- Updated interest rate, maturity, and savings amounts require review of Exhibit 10.1
- Management’s estimated savings are forward-looking and subject to execution and market risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.